2min chapter

Biotech 2050 Podcast cover image

Leading personalized immune medicines, Harlan Robins, CSO & Co-Founder, Adaptive Biotechnologies

Biotech 2050 Podcast

CHAPTER

Genentech's Personalized Cancer Therapy

Harlan: We're in a 800 people person range. And we have different parts to our company that are sort of in different stages. Our big clinical product was for diagnosing blood cancers, which are cancers of your these T and B cells that are the adaptive immune cells can become cancerous. So our same technology can be used for monitoring them. The other big area we're working on is in the auto immune space where we're identifying what the immune system is specifically targeting so that we can develop therapies to block that target.

00:00

Get the Snipd
podcast app

Unlock the knowledge in podcasts with the podcast player of the future.
App store bannerPlay store banner

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode

Save any
moment

Hear something you like? Tap your headphones to save it with AI-generated key takeaways

Share
& Export

Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode